Cargando…
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Epigenetic mechanisms, especially DNA methylation and histone modifications, are dynamic processes that regulate the gene expression transcriptional program in normal and diseased states. The bromodomain and extraterminal (BET) protein family (BRD2, BRD3, BRD4, and BRDT) are epigenetic readers that,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857099/ https://www.ncbi.nlm.nih.gov/pubmed/31780938 http://dx.doi.org/10.3389/fphar.2019.01315 |
_version_ | 1783470696467267584 |
---|---|
author | Morgado-Pascual, Jose Luis Rayego-Mateos, Sandra Tejedor, Lucia Suarez-Alvarez, Beatriz Ruiz-Ortega, Marta |
author_facet | Morgado-Pascual, Jose Luis Rayego-Mateos, Sandra Tejedor, Lucia Suarez-Alvarez, Beatriz Ruiz-Ortega, Marta |
author_sort | Morgado-Pascual, Jose Luis |
collection | PubMed |
description | Epigenetic mechanisms, especially DNA methylation and histone modifications, are dynamic processes that regulate the gene expression transcriptional program in normal and diseased states. The bromodomain and extraterminal (BET) protein family (BRD2, BRD3, BRD4, and BRDT) are epigenetic readers that, via bromodomains, regulate gene transcription by binding to acetylated lysine residues on histones and master transcriptional factors. Experimental data have demonstrated the involvement of some BET proteins in many pathological conditions, including tumor development, infections, autoimmunity, and inflammation. Selective bromodomain inhibitors are epigenetic drugs that block the interaction between BET proteins and acetylated proteins, thus exerting beneficial effects. Recent data have described the beneficial effect of BET inhibition on experimental renal diseases. Emerging evidence underscores the importance of environmental modifications in the origin of pathological features in chronic kidney diseases (CKD). Several cellular processes such as oxidation, metabolic disorders, cytokines, inflammation, or accumulated uremic toxins may induce epigenetic modifications that regulate key processes involved in renal damage and in other pathological conditions observed in CKD patients. Here, we review how targeting bromodomains in BET proteins may regulate essential processes involved in renal diseases and in associated complications found in CKD patients, such as cardiovascular damage, highlighting the potential of epigenetic therapeutic strategies against BET proteins for CKD treatment and associated risks. |
format | Online Article Text |
id | pubmed-6857099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68570992019-11-28 Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases Morgado-Pascual, Jose Luis Rayego-Mateos, Sandra Tejedor, Lucia Suarez-Alvarez, Beatriz Ruiz-Ortega, Marta Front Pharmacol Pharmacology Epigenetic mechanisms, especially DNA methylation and histone modifications, are dynamic processes that regulate the gene expression transcriptional program in normal and diseased states. The bromodomain and extraterminal (BET) protein family (BRD2, BRD3, BRD4, and BRDT) are epigenetic readers that, via bromodomains, regulate gene transcription by binding to acetylated lysine residues on histones and master transcriptional factors. Experimental data have demonstrated the involvement of some BET proteins in many pathological conditions, including tumor development, infections, autoimmunity, and inflammation. Selective bromodomain inhibitors are epigenetic drugs that block the interaction between BET proteins and acetylated proteins, thus exerting beneficial effects. Recent data have described the beneficial effect of BET inhibition on experimental renal diseases. Emerging evidence underscores the importance of environmental modifications in the origin of pathological features in chronic kidney diseases (CKD). Several cellular processes such as oxidation, metabolic disorders, cytokines, inflammation, or accumulated uremic toxins may induce epigenetic modifications that regulate key processes involved in renal damage and in other pathological conditions observed in CKD patients. Here, we review how targeting bromodomains in BET proteins may regulate essential processes involved in renal diseases and in associated complications found in CKD patients, such as cardiovascular damage, highlighting the potential of epigenetic therapeutic strategies against BET proteins for CKD treatment and associated risks. Frontiers Media S.A. 2019-11-08 /pmc/articles/PMC6857099/ /pubmed/31780938 http://dx.doi.org/10.3389/fphar.2019.01315 Text en Copyright © 2019 Morgado-Pascual, Rayego-Mateos, Tejedor, Suarez-Alvarez and Ruiz-Ortega http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Morgado-Pascual, Jose Luis Rayego-Mateos, Sandra Tejedor, Lucia Suarez-Alvarez, Beatriz Ruiz-Ortega, Marta Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title_full | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title_fullStr | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title_full_unstemmed | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title_short | Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases |
title_sort | bromodomain and extraterminal proteins as novel epigenetic targets for renal diseases |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857099/ https://www.ncbi.nlm.nih.gov/pubmed/31780938 http://dx.doi.org/10.3389/fphar.2019.01315 |
work_keys_str_mv | AT morgadopascualjoseluis bromodomainandextraterminalproteinsasnovelepigenetictargetsforrenaldiseases AT rayegomateossandra bromodomainandextraterminalproteinsasnovelepigenetictargetsforrenaldiseases AT tejedorlucia bromodomainandextraterminalproteinsasnovelepigenetictargetsforrenaldiseases AT suarezalvarezbeatriz bromodomainandextraterminalproteinsasnovelepigenetictargetsforrenaldiseases AT ruizortegamarta bromodomainandextraterminalproteinsasnovelepigenetictargetsforrenaldiseases |